Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil<sup>®</sup>) to Tumour Cells Using a Novel TIMP3 Peptide
Doxorubicin is a cytotoxic anthracycline derivative that has been used as a chemotherapeutic in many different forms of human cancer with some success. However, doxorubicin treatment has several side-effects, the most serious of which is cardiomyopathy, that can be fatal. Doxorubicin encapsulation i...
Main Authors: | Mohammed S. Aldughaim, Munitta Muthana, Fatimah Alsaffar, Michael D. Barker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/1/100 |
Similar Items
-
Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site
by: Mohammed S. Aldughaim, et al.
Published: (2021-01-01) -
Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil<sup>®</sup>) in C26 Tumor-Bearing Immunocompetent Mice
by: Takuma Takayama, et al.
Published: (2020-10-01) -
Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
by: Rickard Nordström, et al.
Published: (2021-01-01) -
Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than DoxilⓇ
by: Ruoshi Zhang, et al.
Published: (2020-05-01) -
PEGylated Liposomal Doxorubicin Rechallenge following Doxorubicin-induced Pancreatitis
by: Luke Ardolino, et al.
Published: (2020-12-01)